VSTM
VENTE TOTALE: 22 173 titres (~94 805,40 $ US)
- Insiders
- Paterson Dan
- Total bought
- —
- Total sold
- $94,805
- Last activity
- 2026-08-03
- Last synced
-
2026-08-07 10:27:17
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-05
VSTM presents a high-risk profile driven by persistent cash burn, negative operating margins, and full reliance on external financing, yielding a weak financial health composite of ~41.
The first sentence of the analysis written for VSTM on 2026-08-05 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 82.9% | 100.0% | 0.0% | 100.0% | 100.0% | |
| Ebit Margin | -673.9% | -1258.9% | 0.0% | -2761.0% | -2982.4% | |
| Ebitda Margin | -671.6% | -1258.6% | 0.0% | -2756.4% | -2978.9% | |
| Operating Profit Margin | -550.3% | -1149.6% | 0.0% | -2809.6% | -2991.2% | |
| Pretax Profit Margin | -677.6% | -1304.5% | 0.0% | -2843.3% | -3468.1% | |
| Continuous Operations Profit Margin | -677.6% | -1306.4% | 0.0% | -2843.3% | -3468.1% | |
| Net Profit Margin | -677.6% | -1306.4% | 0.0% | -2843.3% | -3468.1% | |
| Bottom Line Profit Margin | -677.6% | -1306.4% | 0.0% | -2843.3% | -3468.1% | |
| Current Ratio | 3.091 | 3.066 | 5.447 | 4.287 | 5.688 | |
| Quick Ratio | 3.066 | 3.066 | 5.447 | 4.287 | 5.688 | |
| Solvency Ratio | -1.103 | -1.001 | -0.945 | -1.546 | -3.371 | |
| Cash Ratio | 2.837 | 2.868 | 2.953 | 3.459 | 1.143 | |
| Price To Earnings Ratio | -2.556 | -1.413 | -2.056 | -1.050 | -5.000 | |
| Price To Earnings Growth Ratio | 0.146 | 0.186 | 0.154 | 0.148 | 0.733 | |
| Forward Price To Earnings Growth Ratio | 0.146 | 0.186 | 0.154 | 0.148 | 0.733 | |
| Price To Earnings Diluted Ratio | -2.556 | -1.413 | -2.056 | -1.050 | -5.000 | |
| Price To Earnings Diluted Growth Ratio | 0.146 | 0.186 | 0.154 | 0.148 | 0.733 | |
| Price To Book Ratio | 9.355 | -6.390 | 3.129 | 1.635 | 4.083 | |
| Price To Sales Ratio | 17.308 | 18.464 | 0.000 | 29.839 | 174.151 | |
| Price To Free Cash Flow Ratio | -3.891 | -1.762 | -2.076 | -1.217 | -6.658 | |
| Price To Operating Cash Flow Ratio | -3.891 | -1.762 | -2.076 | -1.217 | -6.683 | |
| Debt To Assets Ratio | 0.312 | 0.416 | 0.278 | 0.285 | 0.029 | |
| Debt To Equity Ratio | 1.344 | -1.462 | 0.724 | 0.571 | 0.036 | |
| Debt To Capital Ratio | 0.573 | 3.162 | 0.420 | 0.364 | 0.035 | |
| Long Term Debt To Capital Ratio | 0.572 | 3.442 | 0.411 | 0.341 | 0.003 | |
| Financial Leverage Ratio | 4.309 | -3.514 | 2.610 | 2.006 | 1.241 | |
| Working Capital Turnover Ratio | 0.287 | 0.110 | 0.000 | 0.033 | 0.019 | |
| Operating Cash Flow Ratio | -1.903 | -3.383 | -3.277 | -2.939 | -2.878 | |
| Operating Cash Flow Sales Ratio | -4.448 | -10.477 | 0.000 | -24.527 | -26.060 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.000 | 1.000 | 1.000 | 1.004 | |
| Debt Service Coverage Ratio | -124.091 | -27.630 | -20.093 | -29.667 | -6.133 | |
| Interest Coverage Ratio | -149.498 | -25.199 | -22.248 | -34.131 | -6.158 | |
| Short Term Operating Cash Flow Coverage Ratio | -257.026 | 0.000 | 0.000 | -231.538 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -1.789 | -2.480 | -2.081 | -2.353 | -16.825 | |
| Capital Expenditure Coverage Ratio | 0.000 | -3,741.821 | 0.000 | 0.000 | -272.969 | |
| Dividend Paid And Capex Coverage Ratio | 0.000 | -3,741.821 | 0.000 | 0.000 | -272.969 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -1.960 | -1.097 | -1.721 | -0.414 | -5.551 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 82.9% | ▼-17.1% | ▲6.3% |
| Ebit Margin | -673.9% | ▲585.0% | ▲861.3% |
| Ebitda Margin | -671.6% | ▲587.1% | ▲861.5% |
| Operating Profit Margin | -550.3% | ▲599.2% | ▲949.8% |
| Pretax Profit Margin | -677.6% | ▲626.9% | ▲981.1% |
| Continuous Operations Profit Margin | -677.6% | ▲628.8% | ▲981.5% |
| Net Profit Margin | -677.6% | ▲628.8% | ▲981.5% |
| Bottom Line Profit Margin | -677.6% | ▲628.8% | ▲981.5% |
| Current Ratio | 3.091 | ▲0.025 | ▼-1.224 |
| Quick Ratio | 3.066 | ▲0.000 | ▼-1.245 |
| Solvency Ratio | -1.103 | ▼-0.102 | ▲0.490 |
| Cash Ratio | 2.837 | ▼-0.031 | ▲0.185 |
| Price To Earnings Ratio | -2.556 | ▼-1.144 | ▼-0.141 |
| Price To Earnings Growth Ratio | 0.146 | ▼-0.040 | ▼-0.127 |
| Forward Price To Earnings Growth Ratio | 0.146 | ▼-0.040 | ▼-0.127 |
| Price To Earnings Diluted Ratio | -2.556 | ▼-1.144 | ▼-0.141 |
| Price To Earnings Diluted Growth Ratio | 0.146 | ▼-0.040 | ▼-0.127 |
| Price To Book Ratio | 9.355 | ▲15.745 | ▲6.992 |
| Price To Sales Ratio | 17.308 | ▼-1.155 | ▼-30.644 |
| Price To Free Cash Flow Ratio | -3.891 | ▼-2.129 | ▼-0.770 |
| Price To Operating Cash Flow Ratio | -3.891 | ▼-2.129 | ▼-0.765 |
| Debt To Assets Ratio | 0.312 | ▼-0.104 | ▲0.048 |
| Debt To Equity Ratio | 1.344 | ▲2.806 | ▲1.101 |
| Debt To Capital Ratio | 0.573 | ▼-2.589 | ▼-0.338 |
| Long Term Debt To Capital Ratio | 0.572 | ▼-2.870 | ▼-0.382 |
| Financial Leverage Ratio | 4.309 | ▲7.823 | ▲2.978 |
| Working Capital Turnover Ratio | 0.287 | ▲0.177 | ▲0.198 |
| Operating Cash Flow Ratio | -1.903 | ▲1.480 | ▲0.973 |
| Operating Cash Flow Sales Ratio | -4.448 | ▲6.029 | ▲8.655 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | ▼-0.000 | ▼-0.001 |
| Debt Service Coverage Ratio | -124.091 | ▼-96.461 | ▼-82.569 |
| Interest Coverage Ratio | -149.498 | ▼-124.300 | ▼-102.052 |
| Short Term Operating Cash Flow Coverage Ratio | -257.026 | ▼-257.026 | ▼-159.313 |
| Operating Cash Flow Coverage Ratio | -1.789 | ▲0.691 | ▲3.316 |
| Capital Expenditure Coverage Ratio | 0.000 | ▲3741.821 | ▲802.958 |
| Dividend Paid And Capex Coverage Ratio | 0.000 | ▲3741.821 | ▲802.958 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -1.960 | ▼-0.863 | ▲0.188 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $535.1M | $184.6M | $179.5M | $77.5M | $357.5M | |
| Enterprise value | $406.9M | $138.1M | $143.2M | $29.6M | $339.5M | |
| EV / Sales | 13.16x | 13.81x | 0.00x | 11.40x | 165.35x | |
| EV / Op. cash flow | -2.96x | -1.32x | -1.66x | -0.47x | -6.34x | |
| EV / Free cash flow | -2.96x | -1.32x | -1.66x | -0.47x | -6.32x | |
| EV / EBITDA | -1.96x | -1.10x | -1.72x | -0.41x | -5.55x | |
| Net debt / EBITDA | 0.62x | 0.37x | 0.44x | 0.67x | 0.30x | |
| Current ratio | 3.09x | 3.07x | 5.45x | 4.29x | 5.69x | |
| Income quality | 0.66x | 0.80x | 0.99x | 0.86x | 0.75x | |
| Graham net-net | $0 | -$1 | $2 | $2 | $5 | |
| Tax burden | 100.0% | 100.1% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.5% | 103.6% | 105.0% | 103.0% | 116.3% | |
| Working capital | $151.1M | $64.0M | $117.3M | $71.2M | $87.2M | |
| Invested capital | $168.1M | $65.4M | $118.5M | $73.1M | $89.7M | |
| Return on assets | -85.0% | -128.7% | -58.4% | -77.7% | -65.5% | |
| Operating ROA | -97.8% | -91.5% | -75.2% | -71.6% | -46.7% | |
| Return on tangible assets | -91.1% | -128.7% | -58.4% | -77.7% | -65.5% | |
| Return on equity | -366.2% | 452.1% | -152.3% | -155.8% | -81.3% | |
| Return on invested capital | -97.4% | -160.6% | -74.1% | -98.0% | -67.7% | |
| Return on capital employed | -97.7% | -162.9% | -74.7% | -99.4% | -68.2% | |
| Earnings yield | -39.1% | -70.8% | -48.7% | -95.3% | -19.9% | |
| Free cash flow yield | -25.7% | -56.8% | -48.2% | -82.2% | -15.0% | |
| Capex / Op. cash flow | 0.0% | -0.0% | 0.0% | 0.0% | -0.4% | |
| Capex / Depreciation | 0.0% | 107.7% | 0.0% | 0.0% | 272.2% | |
| Capex / Sales | 0.0% | 0.3% | 0.0% | 0.0% | 9.5% | |
| SG&A / Sales | 262.5% | 436.2% | 0.0% | 962.1% | 1174.6% | |
| R&D / Sales | 370.7% | 813.3% | 0.0% | 1947.5% | 1916.6% | |
| Stock comp / Sales | 30.4% | 73.4% | 0.0% | 232.9% | 375.6% | |
| Intangibles / Total assets | 6.7% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 104d | 7d | 0d | 4d | 92d | |
| Days payables outstanding | 858d | 0d | 0d | 0d | 0d | |
| Operating cycle | 230d | 7d | 0d | 4d | 92d | |
| Cash conversion cycle | -627d | 7d | 0d | 4d | 92d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+189.8%EV / Sales ▼-4.7%EV / EBITDA ▼-78.7%EV / Op. cash flow ▼-1.642Earnings yield ▲+0.316
Profitability
Return on equity ▼-8.184Return on assets ▲+0.437Return on invested capital ▲+0.633Return on capital employed ▲+0.652Operating ROA ▼-0.063Income quality ▼-0.146Tax burden ▼-0.001
Efficiency
Days sales outstanding ▲+96.755Days payables outstanding n/aOperating cycle ▲+223.037Cash conversion cycle ▼-634.554Capex / Sales ▼-0.003R&D / Sales ▼-4.426
Balance-sheet strength
Current ratio ▲+0.026Net debt / EBITDA ▲+0.247Working capital ▲+87157000.000Invested capital ▲+102637000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+49.7%EV / Sales ▼-92.0%EV / EBITDA ▲+64.7%EV / Op. cash flow ▲+3.385Earnings yield ▼-0.192
Profitability
Return on equity ▼-2.849Return on assets ▼-0.195Return on invested capital ▼-0.297Return on capital employed ▼-0.295Operating ROA ▼-0.511Income quality ▼-0.095Tax burden 0.000
Efficiency
Days sales outstanding ▲+12.316Days payables outstanding n/aOperating cycle ▲+138.598Cash conversion cycle ▼-718.993Capex / Sales ▼-0.095R&D / Sales ▼-15.459
Balance-sheet strength
Current ratio ▼-2.597Net debt / EBITDA ▲+0.322Working capital ▲+63995000.000Invested capital ▲+78400000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-06 Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent business progress. “The second quarter marked meaningful progress across our commercial business and pipeline programs, with strong quarter-over-quarter growth for AVMAPKI FAKZYNJA CO-PACK driven by new patient starts and in.
- 2026-07-28 Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--Verastem doses first patient in TARGET-D 203, a registration-directed Phase 2 trial of VS-7375 in KRAS G12D-mutated metastatic colorectal cancer.
- 2026-07-23 Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026 BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its second quarter 2026 financial results and business updates on Thursday, August 6, 2026, at 4:30 pm ET. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investo.
- 2026-07-22 Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--Verastem doses first patient in TARGET-D 202, a registration-directed Phase 2 clinical trial of VS-7375 in KRAS G12D-mutated advanced NSCLC.
- 2026-07-10 Verastem (VSTM) Surges 6.3%: Is This an Indication of Further Gains? Verastem (VSTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 2026-07-02 Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 399,750 restricted stock units to 30 new employees and the grant of stock options to purchase 91,000 shares of its common stock to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee''s acceptance of employment wit.
- 2026-06-23 Verastem, Inc. (VSTM) Discusses Preliminary TARGET-D 101 Data for VS-7375 in KRAS G12D Mutated Cancers Transcript Verastem, Inc. (VSTM) Discusses Preliminary TARGET-D 101 Data for VS-7375 in KRAS G12D Mutated Cancers Transcript
- 2026-06-23 VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--VS-7375 (investigational KRAS G12D ON/OFF inhibitor) demonstrates clinical activity with a favorable safety profile in TARGET-D 101 clinical trial.
- 2026-06-17 Verastem: ''Buy'' Positive RAMP-205 Data And Extensive VS-7375 Registration Program Verastem, Inc. is maintained at a Buy rating, driven by upcoming clinical catalysts and positive early-stage data in KRAS G12D mutant solid tumors. VSTM expects key data readouts from the TARGET-D 101 phase 1/2 study in 2026 and is advancing three phase 2 registration-directed studies for PDAC, NSCLC, and CRC for VS-7375. Positive phase 1b/2a RAMP 205 results in 1st-line metastatic PDAC (86% OS at 6 months, 52% cORR) support further development of avutometinib/defactinib combinations.
- 2026-06-17 Verastem Stock Jumps As Data Shows Strong Survival Trends In Pancreatic Cancer Verastem, Inc. (NASDAQ:VSTM) stock is trading higher on Wednesday as the company announced positive updated results from its RAMP 205 trial, which evaluates the efficacy of its drug combination in treating metastatic pancreatic cancer.